Arbour, K. C., Tawee, T., Yaeger, R., Parikh, A. R., Oberstein, P., Papadopoulos, K. P., … Hong, D. S. (2025). Abstract CT019: Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors. In Cancer Research (Vol. 85, pp. CT019–CT019). American Association for Cancer Research (AACR). https://doi.org/10.1158/1538-7445.am2025-ct019

Arbour, Kathryn C., Tanvetyanon Tawee, Rona Yaeger, Aparna R. Parikh, Paul Oberstein, Kyriakos P. Papadopoulos, John Strickler, et al. “Abstract CT019: Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors.” In Cancer Research, 85:CT019–CT019. American Association for Cancer Research (AACR), 2025. https://doi.org/10.1158/1538-7445.am2025-ct019.

Arbour KC, Tawee T, Yaeger R, Parikh AR, Oberstein P, Papadopoulos KP, et al. Abstract CT019: Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors. In: Cancer Research. American Association for Cancer Research (AACR); 2025. p. CT019–CT019.

Arbour, Kathryn C., et al. “Abstract CT019: Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors.” Cancer Research, vol. 85, no. 8_Supplement_2, American Association for Cancer Research (AACR), 2025, pp. CT019–CT019. Crossref, doi:10.1158/1538-7445.am2025-ct019.

Arbour KC, Tawee T, Yaeger R, Parikh AR, Oberstein P, Papadopoulos KP, Strickler J, Spira A, Powderly J, Barve M, Wang J, Luo J, Hazad NS, Starodub A, LoRusso P, Elgin A, Yang M, Yu W, McCleland M, Lally S, Sohoni S, Hong DS. Abstract CT019: Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors. Cancer Research. American Association for Cancer Research (AACR); 2025. p. CT019–CT019.